The blinqTM Vision Screener in Detection of Amblyopia and Strabismus

center dot PURPOSE: The blinq (Rebion Inc) is a new screening device designed to directly detect amblyopia and strabis-mus rather than amblyopia risk factors. We performed an independent assessment of the effectiveness of the blinq in detecting amblyopia and strabismus.center dot DESIGN: Prospective clinical validity analysis of a screening device based on sensitivity and specificity.center dot METHODS: Children presenting for examination in the pediatric ophthalmology clinic underwent screening with the blinq before examination by a pediatric ophthalmolo-gist blinded to the screening results. Results of the blinq and examination findings of strabismus or amblyopia were compared. center dot RESULTS: In our cohort of 267 children with an average age of 6.3 years, the sensitivity of the blinq to detect am-blyopia or any constant strabismus was 87.5% (78.2%-93.8%) and specificity was 51.3% (43.9%-58.7%). Us-ing the previously described "appropriate referral gold standard" criteria, including children with intermittent strabismus and high refractive error, the sensitivity in-creased to 91.3% and the specificity to 63.2%. We found a high number of children (44 [16%]) upon whom the blinq timed out and were included as automatic referrals. center dot CONCLUSIONS: Our results support use of the blinq as a screening device to detect amblyopia and strabismus in children. (Am J Ophthalmol 2023;250: 20-24. (c) 2023 Elsevier Inc. All rights reserved.)